点击化学
化学
组合化学
纳米技术
计算生物学
材料科学
生物
作者
Julia Schönfeld,Nick Liebisch,Steffen Brunst,Lilia Weizel,Stefan Knapp,Aimo Kannt,Ewgenij Proschak,Kerstin Hiesinger
摘要
The direct-to-biology (D2B) approach enables biological screening of crude reaction mixtures, eliminating the need for purification steps and thereby accelerating drug discovery. In this study, we developed a miniaturized D2B platform for the rapid synthesis of proteolysis targeting chimera (PROTAC) degraders of soluble epoxide hydrolase (sEH). We used copper-catalyzed azide-alkyne cycloaddition and optimized the conditions for 384-well PCR plate applications with 10 μL reaction volumes on a 300 nmol scale. This approach enabled the D2B synthesis of 92 crude PROTACs from azide-functionalized CRBN-ligands and alkyne-linked sEH inhibitors. Biological screening using a HiBiT lytic degradation assay identified two hits that were resynthesized and exhibited subnanomolar DC50 values and degradation efficacy (Dmax). Thus, we established a scalable, cost-effective and time-saving D2B platform for the discovery of PROTACs in very small quantities. This methodology is particularly suitable for early-stage screening and hit validation assessing the degradability of a target.
科研通智能强力驱动
Strongly Powered by AbleSci AI